Mulmit

Revolution Medicines, Inc.Revolution Medicines, Inc.

RVMD Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-310-1,182,369,000-1,131,000,000-5.95
2024-12-310-689,524,000-600,000,000-3.58
2023-12-3111,580,000-487,185,000-436,000,000-3.86
2022-12-3135,380,000-258,279,000-249,000,000-3.08
2021-12-3129,390,000-188,008,000-187,000,000-2.57

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-18Mancini AnthonySee Remarks1,764
2026-09-16Mancini AnthonySee Remarks27
2026-09-16Mancini AnthonySee Remarks1,747
2026-09-16Cislini JeffSVP & General Counsel52
2026-09-16Cislini JeffSVP & General Counsel3,314
2026-09-16Sandler Alan B.Chief Development Officer5
2026-09-16Sandler Alan B.Chief Development Officer336
2026-09-16Anders JackChief Financial Officer61
2026-09-16Anders JackChief Financial Officer3,992
2026-09-16Kelsey Stephen MichaelSee Remarks85
2026-09-16Kelsey Stephen MichaelSee Remarks5,484
2026-09-16Horn Margaret AChief Operating Officer76

8-K events

FiledItems
2026-09-01Entry into a material agreement · Creation of a direct financial obligation
2026-08-26Other events
2026-08-05Results of operations · Financial statements and exhibits
2026-06-22Officer or director change · Submission of matters to a vote
2026-05-06Results of operations · Financial statements and exhibits
2026-04-17Entry into a material agreement · Creation of a direct financial obligation · Other events · Financial statements and exhibits
2026-04-16Other events · Financial statements and exhibits
2026-04-13Other events
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…